Researcher

Kai Han

China Pharmaceutical University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 24, 2026 · JOURNAL ARTICLE

Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer.

Annals of Medicine

A retrospective single-centre cohort study identifies BMI and dyslipidemia as associations with improved PFS in anti-PD-1-treated CRC, supported by exploratory lipidomic profiling, but lacks a control arm and prospective design to establish causation or clinical utility.

PromisingShi-Hong Chen Obesity Wu Jiang

Reported

Sample size142

BMI threshold for improved PFS≥24 kg/m²

p-value for PFS difference by BMI0.001

AUG 10, 2026 · JOURNAL ARTICLE

Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy

Nature Nanotechnology

A mechanistic study with in vitro screening and murine tumour models showing enhanced anti-tumour efficacy in combination with anti-PD-1, but no clinical data or human trials reported.

PromisingYoung Seok Cho Hannah E. Dobson Xingwu Zhou

Reported

Compound identified3,4-dihydroxybenzoic acid

Target cell populationCD8+ T cells

Mechanism: glycolysis suppression…Akt-mTORC1-Myc pathway regulation